Protein engineering and design for drug delivery

Area of Science:

• Biotechnology and Genetic Engineering
• Molecular Medicine
• Oncology

Background:

• Significant research has focused on creating fusion proteins for targeted therapy.
• Fusion proteins combine functional domains of different proteins, retaining individual segment activities.
• These engineered molecules aim to selectively target disease-causing cells or extracellular components.

Purpose of the Study:

• To review the development and therapeutic potential of engineered fusion proteins.
• To highlight the advancement of fusion proteins from preclinical research to clinical trials.
• To discuss the application of fusion proteins in treating specific diseases, including cancer.

Main Methods:

• Genetic construction and expression of fusion proteins.
• Characterization of fusion protein functionality and specificity.
• Preclinical evaluation of therapeutic efficacy.
• Monitoring of clinical trial progression (Phase I, II, and III).

Main Results:

• Fusion proteins successfully retain the functions of their constituent protein domains.
• Many fusion proteins demonstrate significant therapeutic advantages over conventional treatments in preclinical models.
• Several fusion proteins have progressed to Phase I/II clinical trials.
• One fusion protein is currently undergoing Phase III clinical trials for cutaneous T cell lymphoma.

Conclusions:

• Engineered fusion proteins represent a promising therapeutic strategy with demonstrated preclinical efficacy.
• The progression of fusion proteins into late-stage clinical trials underscores their therapeutic potential.
• Targeted fusion proteins offer a potential advancement in the treatment of various diseases, particularly in oncology.